1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

BioFactura Joins Stelara Biosimilar Crowd

US-Based Developer Throws Its Hat Into The Ring For Ustekinumab

 
• By Dave Wallace

Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.

Hands Grey Stand Out From The Crowd
Biosimilar ustekinumab developers are part of a growing crowd • Source: Alamy

US-based biologics firm BioFactura has become the latest to join the crowd of biosimilars developers targeting Janssen’s $8bn Stelara (ustekinumab) brand, announcing the start of Phase I trials for the BFI-751 version of the inflammatory diseases treatment that is being developed by being developed by BioFactura Australia.

Billing the Phase I study for BFI-751 as the “first clinical trial from BioFactura’s pipeline of high-value biosimilar and biodefense drugs,” the company said the candidate – developed using the firm’spatented “StableFast” platform – would undergo a pivotal pharmacokinetics assessment to assess its effects on

More from Biosimilars

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.